The effect of Pluronic on the protein release kinetics of an injectable drug delivery system.

A new class of injectable controlled release depots has been prepared by incorporating materials that preferentially segregate during phase inversion. These consist of blends of poly(ethylene oxide) (PEO)/poly(propylene oxide) (PPO)/poly(ethylene oxide) (PEO) triblock copolymers (Pluronics) with poly(D,L-lactide) (PDLA)/1-methyl-2-pyrrolidinone (NMP) solutions. The effects of preferential segregation on the phase inversion dynamics and in vitro protein release kinetics were examined using dark ground imaging, high performance liquid chromatography (HPLC), scanning electron microscopy (SEM), and confocal microscopy. Variations in Pluronic concentration and molecular weight had an insignificant effect on the internal depot morphologies, however, increasing the concentration and molecular weight did result in increased phase separation rates and, surprisingly, a decrease in the magnitude of the protein burst, though the release profiles still retained a typical burst-type shape. Additionally, increasing the Pluronic concentration beyond a critical point resulted in a transition from a burst-type profile to an extended-release profile. An interpretation of these results in terms of a qualitative model for the protein release mechanism is also given.     

Phase inversion dynamics of PLGA solutions related to drug delivery. Part II. The role of solution thermodynamics and bath-side mass transfer.

The role of solvent properties and bath-side composition on the phase inversion dynamics and in vitro protein release kinetics of polylactic-co-glycolic acid (PLGA) solutions has been examined using dark ground imaging, in vitro release rate, and SEM techniques. Thermodynamic phase diagrams for three model systems (PLGA in 1-methyl-2-pyrrolidinone (NMP), triacetin, and ethyl benzoate) suggest two general classes of precipitation behavior, depending on the relative solvent strength and water miscibility. Drug release from the NMP-based system is primarily governed by the dynamics of phase inversion and exhibits a distinct burst region followed by a much slower release. Alternatively, depots with low solvent/water affinity (PLGA in triacetin or ethyl benzoate) undergo much slower phase inversion, resulting in a less porous, more fluid, two-phase structure that also releases protein more uniformly. Addition of a small chain triglyceride or organic salt to the aqueous receptor bath also evokes a significant increase in the mass transfer rate of protein from the low solvent/non-solvent affinity depots. An interpretation of these results in terms of a qualitative model for the protein release mechanism is also given.     

Experimental investigation and mathematical modeling of Pluronic F127 gel dissolution: drug release in stirred systems.

We have examined the dissolution of Pluronic F127 gels in a USP dissolution apparatus under stirred conditions, and simultaneously monitored the release of model drugs from these gels. The drugs selected were propranolol HCl, metronidazole and cephalexin. Our results show that drug release is zero-order and is controlled by the dissolution of the gel for all the drugs, under various conditions of temperature, F127 concentration, drug concentration, and for stirring speeds between 20 and 80 rpm. The addition of inorganic salts has no significant effect on dissolution rate or drug release. Increasing F127 concentration in the gel decreases gel dissolution and drug release rates. We have developed a predictive mathematical model based on the assumption that uptake of water into the gel and subsequent disentanglement of F127 micelles control gel dissolution. There is good agreement between experimental results and model predictions for stirring speeds above 20 rpm. As stirring speed is decreased to 20 rpm and below, there are discrepancies between actual and predicted values, presumably due to a significant diffusion component that contributes to drug release.     

Controlled delivery of recombinant hirudin based on thermo-sensitive Pluronic F127 hydrogel for subcutaneous administration: In vitro and in vivo characterization.

Here we investigated thermo-sensitive Pluronic(R) F127 (PF127) hydrogel for the controlled release of peptide and protein drugs after subcutaneous injection, using an antithrombotic polypeptide, recombinant hirudin variant-2 (rHV2), as the model drug. The in vitro release experiment performed with a membrane-less model at 37 degrees C showed that the release of antithrombotic activity of rHV2 from PF127 gel followed zero-order kinetics and correlated well with the weight percentage of PF127 dissolved, indicating a dissolution-controlled release mechanism. The in vivo result obtained after subcutaneous injection of rHV2-loaded PF127 gel in normal rats demonstrated that PF127 gel improved the bioavailability, prolonged the antithrombotic effect of rHV2, and induced detectable plasma rHV2 concentration for a longer time in comparison with rHV2 aqueous solution. Differential scanning calorimetry, dynamic light scattering and Fourier transform infrared spectroscopy provided evidence of the interaction between PF127 and rHV2, but such interaction was unlikely to interfere the feasibility of this drug delivery system. Our current in vitro and in vivo study suggested that PF127 gel may be useful as an injectable delivery vehicle for peptides and proteins with short half-lives to prolong their therapeutic effect, increase their bioavailability and improve the clinic outcome.     

Understanding controlled drug release from mesoporous silicates: Theory and experiment

Based on the results of carefully designed experiments upgraded with appropriate theoretical modeling, we present clear evidence that the release curves from mesoporous materials are significantly affected by drug-matrix interactions. In experimental curves, these interactions are manifested as a non-convergence at long times and an inverse dependence of release kinetics on pore size. Neither of these phenomena is expected in non-interacting systems. Although both phenomena have, rather sporadically, been observed in previous research, they have not been explained in terms of a general and consistent theoretical model. The concept is demonstrated on a model drug indomethacin embedded into SBA-15 and MCM-41 porous silicates. The experimental release curves agree exceptionally well with theoretical predictions in the case of significant drug-wall attractions. The latter are described using a 2D Fokker-Planck equation. One could say that the interactions affect the relative cross-section of pores where the local flux has a non-vanishing axial component and in turn control the effective transfer of drug into bulk solution. Finally, we identify the critical parameters determining the pore size dependence of release kinetics and construct a dynamic phase diagram of the various resulting transport regimes.     

Predictability of drug release from cochlear implants

A simplified mathematical theory is presented allowing for in silico simulation of the effects of key parameters of miniaturized implants (size and composition) on the resulting drug release kinetics. Such devices offer a great potential, especially for local drug treatments, e.g. of the inner ear. However, the preparation and characterization of these systems is highly challenging, due to the small system dimensions. The presented mathematical theory is based on Fick's second law of diffusion. Importantly, theoretical predictions do not require the knowledge of many system-specific parameters: Only the "apparent" diffusion coefficient of the drug within the implant matrix is needed. This parameter can be easily determined via drug release measurements from thin, macroscopic films. The validity of the theoretical model predictions was evaluated by comparison with experimental results obtained with a cochlear implant. The latter consisted of miniaturized electrodes, which were embedded in a silicone matrix loaded with various amounts of dexamethasone. Importantly, independent experimental results confirmed the theoretical predictions. Thus, the presented simplified theory can help to significantly speed up the optimization of this type of controlled drug delivery systems, especially if long release periods are targeted (e.g., several months or years). Straightforward experiments with thin, macroscopic films and computer simulations can allow for rapid identification of optimal system design.     

The pH-dependent biphasic release of azidothymidine from a layered composite of PVA disks and P(MMA/MAA) spheres.

A composite device was developed to provide a biphasic drug release using poly(vinyl alcohol) (PVA) and poly(methylmethacrylate-co-methacrylic acid) (P(MMA/MAA)) spheres. Azidothymidine (AZT), an anti-HIV agent with a short biological half-life, was used as the model drug. Dynamic and equilibrium swelling of the polymers, and kinetics of AZT release from these polymers were determined in pH 1.2 and 6.8 buffer solutions. The swelling of PVA and release of AZT from PVA disks were fast and nearly pH-independent, whereas the swelling behavior and drug release kinetics of P(MMA/MAA) spheres were strongly pH-dependent. A swelling interface number for the spheres at pH 6.8 was determined to be Sw&z.Lt;1 and time dependent. Nevertheless, Fickian diffusion might also contribute to the drug release in this system. The composite disks consisting of PVA matrix and P(MMA/MAA) spheres provided prolonged (over 20 h) and more steady release profiles, differing profoundly from individual components. Such release profiles resulted from the second phase release at pH 6.8 and the presence of PVA layer. The relative drug loading in the matrix could be tailored to produce release profiles varying from a distinct bimodal release to a pseudo zero-order release with an initial burst.     

Sustained release ketoprofen microparticles with ethylcellulose and carboxymethylethylcellulose.

Microparticulate systems for sustained release of ketoprofen were prepared and evaluated by monitoring drug release in the JP XIII second fluid, pH 6.8. All the microparticulate dosage forms were prepared using ketoprofen in the form of calcium salt (KP-Ca). Simple ethylcellulose microparticles of KP-Ca (EC-MP) exhibited the fairly rapid release in the first phase with slower release in the late period. Most of the drug was released from EC-MP showing high drug content. For polymer-coated microparticles of ketoprofen, Eudragit microparticles of KP-Ca (ER-MP) were first prepared, and then coated with ethylcellulose or with a mixture of carboxymethylethylcellulose and ethylcellulose to produce ethylcellulose-coated (EC-coat) and the mixture-coated microparticles (CMEC/EC-coat), respectively. Some polymer-coated microparticles showed drug release at nearly zero-order rate. Especially, CMEC/EC-coat prepared at a CMEC:EC ratio of 1:1 (w/w), named formation I, could supply the drug constantly and efficiently for about half a day except for an initial rapid release. When formation I was administered intraduodenally to rats, the plasma concentration of ketoprofen could be maintained at a nearly constant level. Kinetic analysis demonstrated that formation I showed a nearly zero-order release rate in vivo consistent with that observed in vitro.     

Factors affecting acoustically triggered release of drugs from polymeric micelles.

A custom ultrasonic exposure chamber with real-time fluorescence detection was used to measure acoustically-triggered drug release from Pluronic P-105 micelles under continuous wave (CW) or pulsed ultrasound in the frequency range of 20 to 90 kHz. The measurements were based on the decrease in fluorescence intensity when drug was transferred from the micelle core to the aqueous environment. Two fluorescent drugs were used: doxorubicin (DOX) and its paramagnetic analogue, ruboxyl (Rb). Pluronic P-105 at various concentrations in aqueous solutions was used as a micelle-forming polymer. Drug release was most efficient at 20-kHz ultrasound and dropped with increasing ultrasonic frequency despite much higher power densities. These data suggest an important role of transient cavitation in drug release. The release of DOX was higher than that of Rb due to stronger interaction and deeper insertion of Rb into the core of the micelles. Drug release was higher at lower Pluronic concentrations, which presumably resulted from higher local drug concentrations in the core of Pluronic micelles when the number of micelles was low. At constant frequency, drug release increased with increasing power density. At constant power density and for pulse duration longer than 0.1 s, peak release under pulsed ultrasound was the same as stationary release under CW ultrasound. Released drug was quickly re-encapsulated between the pulses of ultrasound, which suggests that upon leaving the sonicated volume, the non-extravasated and non-internalized drug would circulate in the encapsulated form, thus preventing unwanted drug interactions with normal tissues.     

Role of crystallization in the phase inversion dynamics and protein release kinetics of injectable drug delivery systems

The role of polymer crystallization in the phase inversion dynamics and in vitro protein release kinetics of semi-crystalline poly (-caprolactone) and amorphous poly ( , -lactide) (PDLA) blend solutions has been examined using high performance liquid chromatography (HPLC), scanning electron microscopy (SEM), and differential scanning calorimetry (DSC) techniques. Varying the degree of crystallizability of the solutions led to the emergence of two general classes of depots. Depots with a high degree of crystallinity are characterized by porous morphologies indicative of solid–liquid (s–l) de-mixing and delayed burst release profiles. Alternatively, depots with a low degree of crystallinity are characterized by dense morphologies formed by mild liquid–liquid (l–l) phase separation and slow, uniform protein release rates. An interpretation of these results in terms of a qualitative model for the protein release mechanism is also given.     

Development of oral controlled release preparations, a PVA swelling controlled release system (SCRS). I. Design Of SCRS and its release controlling factor.

Polyvinyl alcohol (PVA) is hydrophilic and swells easily by absorbing water. Some grades of PVA, whose degree of hydrolysis is 96.0 and 97.5 mol%, showed volume expansion of 500% by swelling at 37 degrees C. This expansion was inhibited by swelling controlling agents, namely salts. Based on this unique property of PVA, a new type of controlled release system was developed. The release rate was controlled by the content of PVA and a swelling controlling agent in the core tablet, and the composition and coating level of the film. Emedastine difumarate was incorporated into the system. At the initial stage of drug release, the rate of release was determined by the permeation through the membrane - a mixture of ethylcellulose and hydroxypropyl methylcellulose. After the membrane burst by the swelling of PVA, the release rate was controlled by the PVA matrix. Release patterns of zero-order, two phase zero-order, and rapid release after lag-time were obtained with this system.     

Drug release characteristics of unimolecular polymeric micelles.

Biodegradable, unimolecular polymeric micelles possess several features that are attractive for drug delivery applications: Thermodynamic stability, ability to encapsulate and solubilize a hydrophobic guest molecule, biodegradability, as well as size and surface characteristics that prevent rapid clearance by the RES. Here we investigate the potential of these unimolecular polymeric micelles to release a drug for an extended time. Lidocaine was used as a model drug for in vitro studies using a horizontal diffusion cell and cellulose membrane that prevented polymer transport from the source to the receiver compartment. The transport of free lidocaine from source to receiver under sink conditions was zero-order and complete within 8 h. The transport of lidocaine initially encapsulated in polymer was zero-order for the first 14 h, and 96% of the lidocaine was detected within 24 h.     

Biodegradable hollow fibres for the controlled release of hormones

Poly(l-lactide), (PLLA), hollow fibres were prepared using a dry-wet phase inversion spinning process. The effect of several spinning parameters (i.e. bore medium flow rate, spinning dope extrusion rate, fibre take-up rate, and spinning height) on the hollow fibre dimensions is reported. The use of several spinning systems (i.e. different solvent/non-solvent pairs with or without additive) resulted in PLLA hollow fibres with varying asymmetric membrane structures, i.e. a porous matrix covered by an internal and external skin varying from very thick and dense to very thin and porous. Some of the differences in membrane structure were qualitatively explained on the basis of a model developed by Reuvers [52] for the formation of flat-sheet membranes by immersion precipitation. Release experiments were carried out using PLLA hollow fibres filled with a 25 wt.% dispersion of micronized ³H-levonorgestrel in castor oil, and a receiving fluid consisting of 40 wt.% aqueous ethanol. The hollow fibre levonorgestrel release rates were found to be dependent on the membrane structure of the hollow fibre wall. For the different hollow fibre samples, zero-order levonorgestrel release rates were found, in the range of 0.1–10 μg/cm/day. Possible release mechanisms are discussed. Preliminary in vivo (rabbit) release experiments showed that constant levonorgestrel blood plasma levels could be obtained for a period up to 210 days. It is concluded that the new biodegradable hollow fibre reservoir device shows very promising properties for possible application as a long-acting contraceptive delivery system.     

Release kinetics of hydrophobic and hydrophilic model drugs from pluronic F127/poly(lactic acid) nanoparticles.

Poly(lactic acid) (PLA) was successfully grafted to both ends of Pluronic F127 block copolymers (PEO-PPO-PEO) to obtain amphiphilic PLA-F127-PLA block copolymers. The block composition and structure of PLA-F127-PLA block copolymers were studied by nuclear magnetic resonance (NMR), gel permeation chromatography (GPC), differential scanning calorimetric (DSC) and wide angle X-ray diffraction (WXRD) techniques. Data from DSC and WXRD measurements indicated that Tg and Tm of PLA blocks in PLA-F127-PLA block polymers are lower than those of PLA homopolymer. Furthermore, Tm and crystallinity of PLA blocks decrease with decreasing PLA block length in PLA-F127-PLA block copolymers. The release behaviors of both hydrophobic 9-(methylaminomethyl)anthracene (MAMA) and hydrophilic procaine hydrochloride (PrHy) model drugs from PLA-F127-PLA nanoparticles with vesicular structure in PBS solution at 37 degrees C were examined by UV spectroscopy. The release kinetics of both MAMA and PrHy model drugs from PLA-F127-PLA nanoparticles exhibit burst release characteristics, which are believed to be controlled by concentration gradient resulting from the slow hydrolytic degradation of PLA segments.     

A model of dissolution-controlled,diffusional drug release from non-swellable polymeric microspheres

A new model was developed to account for the kinetics of drug release from porous, non-swellable polymeric microparticles in the case where both drug dissolution and diffusion mechanisms control the overall release process. The model incorporates a linear first-order dissolution term and the transient Fickian diffusion equation, and is solved for perfect sink and surface-dependent boundary conditions. Long-term limiting solutions indicate that after an initial time-dependent period of release, the release rate becomes independent of time. Numerical solutions are provided which indicate the effects of particle size, solute diffusion coefficient and solute dissolution rate on the release kinetics.     

Theoretical analysis of inward hemispheric release above and below drug solubility.

A detailed analysis of inward diffusional drug release from devices with hemispheric and related geometries is presented. When drug is loaded below its solubility, an infinite series describes drug concentration profiles and release kinetics, with an excellent approximation resulting when only one term of this series is retained. A connection between this geometric setting and diffusion in constricted porous domains is pointed out, as is the utility of mean first passage times and mean residence times derived for this model. For the case of drug loaded above its solubility, the pseudosteady state (PSS) approximation of Béchard and McMullen [J. Pharm. Sci. 77 (1988) 222] is compared against numerical results calculated for the full model in which the PSS assumption is removed. A close match is observed. Asymptotic analysis of the PSS expressions shows that the previously used zero-order release assumption is not quite correct, even at later times, and this affects parameter estimation procedures. A comparison between the model of Béchard and McMullen and earlier obtained experimental data [J. Pharm. Sci. 72 (1983) 17] reveals some qualitative discrepancies that are yet to be explained.     

Phase inversion dynamics of PLGA solutions related to drug delivery.

Dark ground optical microscopy, electron microscopy, and high performance liquid chromatography (HPLC) have been used to quantify the effects of formulation changes on the phase inversion dynamics and in vitro drug release properties of a PLGA-based drug delivery system. Gel growth rates and water influx rates are determined from plots of the square of the respective front motion with time. Results show that additives that accelerate the solution gelation rate at constant morphology result in high initial release rates. Conversely, additives that slow the rate of gelation dramatically reduce the initial drug release rate and lead to a more dense sponge-like morphology. Moreover, the phase inversion dynamics and morphology are the same regardless of whether the solutions are quenched with water, a PBS buffer solution or horse serum.     

Precise control of PLG microsphere size provides enhanced control of drug release rate.

An important limitation in the development of biodegradable polymer microspheres for controlled-release drug delivery applications has been the difficulty of specifically designing systems exhibiting precisely controlled release rates. Because microparticle size is a primary determinant of drug release, we developed a methodology for controlling release kinetics employing monodisperse poly(D,L-lactide-co-glycolide) (PLG) microspheres. We fabricated 20-, 40- and 65-microm diameter rhodamine-containing microspheres and 10-, 50- and 100-microm diameter piroxicam-containing microspheres at various loadings from 1 to 20%. In vitro release kinetics were determined for each preparation. Drug release depended strongly on microsphere diameter with 10- and 20-microm particles exhibiting concave-downward release profiles while larger particles resulted in sigmoidal release profiles. Overall, the rate of release decreased and the duration increased with increasing microsphere size. Release kinetics from mixtures of uniform microspheres corresponded to mass-weighted averages of the individual microsphere release kinetics. Appropriate mixtures of uniform microspheres were identified that provided constant (zero-order) release of rhodamine and piroxicam for 8 and 14 days, respectively. Mixing of uniform microspheres, as well as control of microsphere size distribution, may provide an improved methodology to tailor small-molecule drug-release kinetics from simple, biodegradable-polymer microparticles.     

Influence of the drug compatibility with polymer solution on the release kinetics of electrospun fiber formulation.

The electrospun fiber mat for drug delivery is a novel formulation with promising clinical applications in the future. The influence of the solubility and compatibility of drugs in the drug/polymer/solvent system on the encapsulation of the drug inside the poly(L-lactide) (PLLA) electrospun fibers and the release behavior of this formulation were examined by using paclitaxel, doxorubicin hydrochloride and doxorubicin base as model drugs. The burst release of the drugs can be avoided by using compatible drugs with polymers, and the drug release can follow nearly zero-order kinetics due to the degradation of the PLLA fibers in the presence of proteinase K.     

Temperature-controlled content release from liposomes encapsulating Pluronic F127.

Temperature-dependent internal content release from liposomes was examined using di-oleoylphosphatidylcholine (DOPC)/cholesterol liposomes with encapsulated Pluronic F127 molecules. The interaction of Pluronic F127 with the lipid bilayer at elevated temperature causes the release of encapsulated contents. Content release was measured using fluorescent markers of two different sizes: small, carboxyfluorescein (CF), and large, bovine serum albumin-conjugated fluorescein iso-thiocyanate (BSA-FITC). Release of CF was studied using fluorescence de-quenching, while that of BSA-FITC was studied using fluorescence emission quenching due to fluorescence resonance energy transfer (FRET). Temperature-controlled complete internal content release was achieved at a precise temperature by controlling the concentration of the encapsulated Pluronic. Increasing cholesterol % in the liposome composition resulted in a sharper transition with temperature in content release. The onset temperature of content release increased with decrease in Pluronic concentration. For the same Pluronic concentration, the onset temperature also depended on the size of the encapsulated marker and was higher for larger markers. We have established that onset of content release is determined by the critical micellar temperature (CMT) of the Pluronic. Temperature-sensitive liposomes, made stealth using di-stearoyl(polyethylene glycol 5000) phosphatidylethanolamine (DSPEG5000PE) in conjunction with Pluronic F127, had similar temperature sensitivity and efficiency in content release compared to the non-stealth liposomes.